These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Physicochemical Stability of Monoclonal Antibodies: A Review. Le Basle Y; Chennell P; Tokhadze N; Astier A; Sautou V J Pharm Sci; 2020 Jan; 109(1):169-190. PubMed ID: 31465737 [TBL] [Abstract][Full Text] [Related]
10. Subcutaneous delivery of monoclonal antibodies: How do we get there? Viola M; Sequeira J; Seiça R; Veiga F; Serra J; Santos AC; Ribeiro AJ J Control Release; 2018 Sep; 286():301-314. PubMed ID: 30077735 [TBL] [Abstract][Full Text] [Related]
11. A novel in vitro method to model the fate of subcutaneously administered biopharmaceuticals and associated formulation components. Kinnunen HM; Sharma V; Contreras-Rojas LR; Yu Y; Alleman C; Sreedhara A; Fischer S; Khawli L; Yohe ST; Bumbaca D; Patapoff TW; Daugherty AL; Mrsny RJ J Control Release; 2015 Sep; 214():94-102. PubMed ID: 26210441 [TBL] [Abstract][Full Text] [Related]
12. Improving the outcomes of biopharmaceutical delivery via the subcutaneous route by understanding the chemical, physical and physiological properties of the subcutaneous injection site. Kinnunen HM; Mrsny RJ J Control Release; 2014 May; 182():22-32. PubMed ID: 24631859 [TBL] [Abstract][Full Text] [Related]
13. A hydrophobic interaction chromatography method suitable for quantitating individual monoclonal antibodies contained in co-formulated drug products. Luo L; Jiang B; Cao Y; Xu L; Shameem M; Liu D J Pharm Biomed Anal; 2021 Jan; 193():113703. PubMed ID: 33147536 [TBL] [Abstract][Full Text] [Related]
14. Defining the right diluent for intravenous infusion of therapeutic antibodies. Luo S; McSweeney KM; Wang T; Bacot SM; Feldman GM; Zhang B MAbs; 2020; 12(1):1685814. PubMed ID: 31774346 [TBL] [Abstract][Full Text] [Related]
15. Buffer-free therapeutic antibody preparations provide a viable alternative to conventionally buffered solutions: from protein buffer capacity prediction to bioprocess applications. Bahrenburg S; Karow AR; Garidel P Biotechnol J; 2015 Apr; 10(4):610-22. PubMed ID: 25641961 [TBL] [Abstract][Full Text] [Related]
17. Protein Stability After Administration: A Physiologic Consideration. Schuster J; Kamuju V; Mathaes R J Pharm Sci; 2023 Feb; 112(2):370-376. PubMed ID: 36202247 [TBL] [Abstract][Full Text] [Related]
18. Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model. Varkhede N; Forrest ML J Pharm Pharm Sci; 2018; 21(1s):130s-148s. PubMed ID: 30011390 [TBL] [Abstract][Full Text] [Related]
19. Stability of buffer-free freeze-dried formulations: A feasibility study of a monoclonal antibody at high protein concentrations. Garidel P; Pevestorf B; Bahrenburg S Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):125-39. PubMed ID: 26455339 [TBL] [Abstract][Full Text] [Related]
20. In vitro model for predicting bioavailability of subcutaneously injected monoclonal antibodies. Bown HK; Bonn C; Yohe S; Yadav DB; Patapoff TW; Daugherty A; Mrsny RJ J Control Release; 2018 Mar; 273():13-20. PubMed ID: 29355621 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]